- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory panel to consider OTC status of NSAIDs
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
BETHLEHEM, Pa. — The Food and Drug Administration has approved a new Daiichi Sankyo manufacturing center that the company said would strengthen its domestic and global supply chain.
The Japan-based drug maker said it received FDA approval to package products at the plant, in Bethlehem, Pa. The company said it would be the first noncontracted U.S. manufacturing operation. The plant employs 39 people, and there are plans to hire more.
The 140,000-sq.-ft. plant will package some of Daiichi Sankyo's cardiovascular and metabolic drugs, including treatments for high blood pressure, heart disease, diabetes and lipid disorders.